Show item record

dc.contributor.authorSarathy, Kiran
dc.contributor.authorWells, George A.
dc.contributor.authorSingh, Kuljit
dc.contributor.authorCouture, Etienne
dc.contributor.authorChong, Aun-Yeong
dc.contributor.authorRubens, Fraser
dc.contributor.authorLordkipanidzé, Marie
dc.contributor.authorTanguay, Jean-Francois
dc.contributor.authorSo, Derek
dc.date.accessioned2021-02-23T14:23:36Z
dc.date.availableNO_RESTRICTIONfr
dc.date.available2021-02-23T14:23:36Z
dc.date.issued2021
dc.identifier.urihttp://hdl.handle.net/1866/24874
dc.publisherWileyfr
dc.rightsCe document est mis à disposition selon les termes de la Licence Creative Commons Attribution - Pas d’utilisation commerciale 4.0 International. / This work is licensed under a Creative Commons Attribution - NonCommercial 4.0 International License.
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.subjectAcute coronary syndromefr
dc.subjectAntiplateletfr
dc.subjectCoronary artery bypass graft surgeryfr
dc.titlePlatelet quiescence in patients with acute coronary syndrome undergoing coronary artery bypass graft surgeryfr
dc.typeArticlefr
dc.contributor.affiliationUniversité de Montréal. Faculté de pharmaciefr
dc.identifier.doi10.1161/JAHA.120.016602
dcterms.abstractBACKGROUND: The optimal antiplatelet strategy for patients with acute coronary syndromes who require coronary artery bypass surgery remains unclear. While a more potent antiplatelet regimen will predispose to perioperative bleeding, it is hypothesized that through “platelet quiescence,” ischemic protection conferred by such therapy may provide a net clinical benefit. METHODS AND RESULTS: We compared patients undergoing coronary artery bypass surgery who were treated with a more potent antiplatelet inhibition strategy with those with a less potent inhibition through a meta-analysis. The primary outcome was all-cause mortality after bypass surgery. The analysis identified 4 studies in which the antiplatelet regimen was randomized and 6 studies that were nonrandomized. Combining all studies, there was an overall higher mortality with weaker strategies compared with more potent strategies (odds ratio, 1.38; 95% CI, 1.03–1.85; P=0.03). CONCLUSIONS: Our findings support the concept of platelet quiescence, in reducing mortality for patients with acute coronary syndrome requiring coronary artery bypass surgery. This suggests the routine up-front use of potent antiplatelet regimens in acute coronary syndrome, irrespective of likelihood of coronary artery bypass graft.fr
dcterms.isPartOfurn:ISSN:2047-9980fr
dcterms.languageengfr
UdeM.ReferenceFournieParDeposanthttps://pubmed.ncbi.nlm.nih.gov/33599134/fr
UdeM.VersionRioxxVersion publiée / Version of Recordfr
oaire.citationTitleJournal of the American Heart Associationfr
oaire.citationVolume10fr


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show item record

Ce document est mis à disposition selon les termes de la Licence Creative Commons Attribution - Pas d’utilisation commerciale 4.0 International. / This work is licensed under a Creative Commons Attribution - NonCommercial 4.0 International License.
RightsCe document est mis à disposition selon les termes de la Licence Creative Commons Attribution - Pas d’utilisation commerciale 4.0 International. / This work is licensed under a Creative Commons Attribution - NonCommercial 4.0 International License.